Pharma²⁸ connects biotech innovation with rare disease opportunities across international markets.
Pharma²⁸ is a rare disease intelligence and market access platform based in Kendall Square, Cambridge, at the center of the Boston biotech ecosystem. We support biotech companies developing therapies for rare and ultra-rare diseases by helping them evaluate, structure and activate clinical, regulatory, data and patient-access opportunities in Brazil and other international markets.
Our work combines medical expertise, market intelligence, strategic partnerships, regulatory awareness, physician engagement and AI-enabled data infrastructure.
Rare Disease Opportunity Assessment
We help biotech companies evaluate whether Brazil or other international markets may be relevant for a specific rare disease therapy or clinical program.
This includes assessment of disease burden, unmet medical need, potential patient cohorts, physician expertise, clinical feasibility, regulatory considerations and strategic alignment.
Rare disease programs require credibility with the right physicians, investigators and institutions.
Pharma²⁸ supports clinical feasibility by identifying relevant centers of excellence, mapping specialist networks, evaluating potential patient populations and connecting biotech companies with experienced medical leaders and research partners.
Brazil can offer significant opportunities for rare disease therapies, but successful entry requires more than registration or distribution.
Pharma²⁸ helps companies understand and activate the Brazilian opportunity through clinical, regulatory, institutional, data and patient-access strategy.
We support companies in evaluating how Brazil may contribute to clinical validation, real-world evidence generation, early access, patient identification and long-term market development.
In rare and ultra-rare diseases, the central challenge is often not only access to treatment — it is finding the right patients and understanding where they may be concentrated.
Pharma²⁸ integrates medical expertise, curated disease evidence, clinical and laboratory data interpretation, physician insight and AI-enabled data infrastructure to support patient identification, diagnostic compatibility assessment, cohort mapping and evidence-based decision-making.
The right clinical relationships can determine whether an international strategy becomes credible and actionable.
Pharma²⁸ helps biotech companies engage physicians, academic centers, specialty institutions and clinical leaders with relevant disease-area expertise and institutional credibility.
Pharma²⁸ supports biotech companies in understanding the regulatory and access context for Brazil and other international markets.
We help companies evaluate possible pathways for clinical studies, early access, compassionate use, evidence generation and long-term registration or access strategies, working alongside appropriate regulatory and legal partners when needed.
Brazil's clinical ecosystem contains significant real-world experience, institutional knowledge and underused data assets.
Pharma²⁸ helps biotech companies explore how real-world evidence, clinical datasets, physician insight and local medical experience can support development decisions, evidence generation, patient mapping and market-access strategy.
Pharma²⁸ connects biotech companies with the physicians, institutions, research centers, patient-access stakeholders and strategic partners needed to move rare disease programs forward responsibly.
Our role is to help align innovation with clinical need, institutional credibility, local expertise and long-term access potential.
From strategic alignment to a practical path forward.
Pharma²⁸ begins with strategic alignment. We assess the therapy, disease area, target population, clinical context, market opportunity, regulatory considerations, data landscape and local stakeholder ecosystem.
From there, we help define a practical path forward, which may include:
Disease and market opportunity assessment
Where a therapy may be clinically and strategically relevant.
Clinical expert mapping
Physicians and centers with disease-area credibility.
Patient cohort and diagnostic pathway analysis
Where and how relevant patients may be identified.
Regulatory and access pathway review
Clinical studies, early access, evidence and registration.
Institutional and academic engagement
Trusted collaborations with credible partners.
Real-world evidence planning
How local data can support development decisions.
Early access or clinical collaboration strategy
Structured pathways aligned with medical need.
Local partnership development
Institutional trust and long-term alignment.
Strategic execution support
From assessment through activation.
A partner for rare disease development, not only market access.
Rare disease development requires more than market access. It requires a partner that understands biotech innovation, clinical credibility, patient identification, regulatory complexity, institutional trust and the strategic value of data.
Pharma²⁸ provides that bridge. Based in Kendall Square, Cambridge, and connected to Brazil's clinical and academic ecosystem, Pharma²⁸ helps biotech companies turn international rare disease opportunities into structured, credible and actionable pathways.
We are especially focused on programs where scientific innovation, unmet medical need, patient identification and international access opportunities intersect.
Biotech startups
Early-stage companies advancing rare disease therapies.
Rare disease companies
Programs anchored in high unmet medical need.
Clinical development teams
Leaders building international clinical pathways.
Medical affairs teams
Physician engagement and evidence generation.
Business development leaders
Structuring responsible international expansion.
Investors and venture-backed companies
Capital aligned with strategic rare disease value.
Academic and clinical research partners
Institutions supporting translational insight.
Physicians and centers of excellence
Disease-area experts and specialty institutions.
Strategic healthcare stakeholders
Patient-access, policy and institutional leaders.
If your company is developing a therapy for a rare or ultra-rare disease, Pharma²⁸ can help assess whether Brazil or another international market should be part of your clinical, regulatory, data or patient-access strategy.
We help turn opportunity into a structured pathway — clinically grounded, data-informed and designed for responsible international growth.
Let's connect.
If you are exploring international opportunities for a rare disease therapy, clinical program, data initiative or strategic partnership, we would welcome the opportunity to connect.